α-Synuclein

α-Synuclein (61-75) is a peptide fragment derived from the larger protein α-Synuclein, which is predominantly found in presynaptic nerve terminals and considered a biomarker candidate for Parkinson's disease (PD).

SynuClean-D (SC-D) is an α-synuclein aggregation inhibitor that prevents fibril propagation, disrupts mature amyloid fibrils, and abolishes dopaminergic neuron degeneration in an animal model of Parkinson's disease.

alphaSYN-IN-NAB2, a neuron-protective agent, is a protein encoded by the NAB2 gene. NAB2 effectively and selectively protects a variety of cells from alpha-SYN toxicity. NAB2 promotes endosomal transport dependent on E3 ubiquitin ligase Rsp5/Nedd4. NAB2 identifies a viable molecular node in alpha-SYN biology that corrects multiple aspects of its underlying pathology, including dysfunctional endosomes and endoplasmic reticulum to Golgi vesicles transport. NAB2 is involved in cellular processes such as cell differentiation, apoptosis and stress response, and can be used to study cancer, neurodevelopment and neuronal activity.

ELN484228 is a α-synuclein blocker. α-synuclein is a key protein in Parkinson's disease.

Buntanetap ((+)-Phenserine) is an orally active inhibitor of polyneurotoxic proteins (TINAPs) for the study of neurological disorders, endocrine and metabolic disorders, and cardiovascular diseases.

Minzasolmin(DLX-313) is an alpha-synuclein misfolding inhibitor for the study of Parkinson's disease.

Cinpanemab (BIIB054) is a novel human monoclonal antibody with affinity for alpha-synuclein residues 1-10. Cinpanemab can be used to study Parkinson's disease and related diseases.

YTX-465 is an inhibitor of both stearoyl-CoA desaturase(IC50s = 39 nM) and Ole1 (IC50s = 30.4 μM).

Corynoxine B (Cory B), a natural alkaloid isolated from Uncaria rhynchophylla (Miq. ), is an autophagy inducer that enhances the activity of Beclin 1/VPS34 complex and increases autophagy by facilitating the interaction between Beclin 1 and HMGB1/2, which may ameliorate Alzheimer's disease. NVP-BAG956 (NVP-BAG956)

α-Synucleinmodulator 1 (Compound 7k) acts as a modulator of α-synuclein. In an ACN/PBS (1:1) buffer solution, it exhibits maximum absorption and emission wavelengths at 386 nm and 603 nm, respectively.

tau Protein/α-synuclein-IN-2 (Compound 14T) is a tau and α-synuclein inhibitor capable of crossing the blood-brain barrier. It reduces α-synuclein oligomerization in a dose-dependent manner through a thiourea linker structure. In biosensor cells, tau Protein/α-synuclein-IN-2 prevents tau aggregation seed effects. In the M17D neuroblastoma model, this compound exhibits anti-inclusion effects and reduces Aβ plaque formation. tau Protein/α-synuclein-IN-2 shows potential for Alzheimer's and Parkinson's disease research.

α-Synucleininhibitor 11 (compound 1) is a selective inhibitor of α-synuclein (α-syn) oligomer formation. It does not inhibit tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synucleininhibitor 11 can be utilized for Parkinson's disease (PD) research.

PROTACα-synuclein degrader 6 (compound T3) is a PROTAC degrader of α-synuclein and tau, with an EC50 of 1.57 μM and 4.09 μM, respectively. This compound plays a significant role in neurodegenerative disease (ND) research.

α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation, suitable for research in neurological disorders.

α-Synucleininhibitor 13 is an inhibitor of α-synuclein (α-Syn). It can prevent the aggregation of α-Syn protein and disassemble already formed fibrils, primarily used in Parkinson's disease research.

α-synuclein-IN-15 (Compound 1) is an inhibitor of α-synuclein fibrillation with an IC50 value of 18 μM. It holds potential for research in neurodegenerative diseases, including Parkinson's disease and Lewy body dementia.

α-synuclein-IN-16 (Compound H1) is an inhibitor of α-synuclein. It effectively suppresses secondary nucleation during α-synuclein aggregation and can be utilized in Parkinson's disease research.

α-Synuclein-IN-18 (Compound Mol D) is an inhibitor of the autocatalytic proliferation of α-synuclein (α-Synuclein) aggregates. It selectively binds to a conserved binding pocket on the surface of α-synuclein fibrils, delaying the aggregation process and tripling the aggregation T1/2. Furthermore, α-Synuclein-IN-18 reduces the formation of toxic α-synuclein oligomers, thereby mitigating neurotoxicity. This compound is valuable for Parkinson's disease research.

α-Synuclein inhibitor 3 (Compound 7g) is a potent inhibitor of α-synuclein (α-Syn) aggregation, with potential applications in Parkinson's disease research [1].

α-Synuclein inhibitor 4 (compound 3gh) is a highly effective, blood-brain barrier-permeable inhibitor of α-Synuclein aggregation, demonstrating potent activity with an IC50 value of 0.98 μM and an inhibition ratio of 91.2% at 30 μM [1].

α-Synuclein inhibitor 6 (compound 3ge) is a blood-brain barrier-permeable agent that effectively inhibits α-Synuclein (α-Syn) aggregation, demonstrating a potent IC50 value of 1.70 μM and achieving an inhibition ratio of 94.4% at 30 μM [1].

α- Synuclein inhibitor 7 (compound 3gf) is effective α- Synuclein ( α- Syn) aggregation inhibitor, IC50 is 1.95 μM, inhibition rate at 30μM was 85.8%. α- Synuclein inhibitor 7 has blood-brain barrier permeability.

Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual inhibitor of Dyrk1A (IC50: 177 nM) and α-synuclein aggregation (IC50: 10.5 μM), characterized by CNS permeability and neuroprotective activity.

α-Synuclein inhibitor 5 is a potent inhibitor of α-Synuclein (α-Syn) aggregation across the blood-brain barrier (IC50: 1.22 μM), with 94.3% inhibition at 30 μM.